Skip to main content
Premium Trial:

Request an Annual Quote

Goldman Sachs Downgrades Cepheid to 'Neutral'

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Goldman Sachs on Tuesday downgraded Cepheid shares to "Neutral" from "Buy," citing the stock's outperformance compared to its peer group and a less attractive risk/reward at current levels.

In a research note, Issac Ro noted strong performance by Cepheid's stock and expected continued growth at the company, but expressed concern over its high price-to-sales multiple of 7.4 times, compared to a median of 2.6 times for its peer group.

"As a result, we move to the sidelines with Cepheid," Ro said.

He is maintaining a six-month price target of $35 on Cepheid's stock, as well as revenue estimates of $259.5 million for 2011 and $334.4 million for 2012. EPS estimates for 2011 and 2012 also were unchanged and are anticipated to be $.09 and $.53, respectively.

Ro said that an expanded test menu, stronger distribution to smaller hospitals, and broader use of molecular testing methods should continue to drive adoption of Cepheid's technology, and in 2011 the firm's installed base is expected to grow 27 percent year over year.

"The company's broadening test portfolio and larger footprint should drive higher consumable usage, which we expect to create a positive volume and mix benefit on gross margins," he said.

Ro added that Cepheid could make for an attractive M&A target "based on our belief that CPHD's growing installed base and expanding test menu is a unique asset in the diagnostics space."

In afternoon trading today on Nasdaq, Cepheid shares were down nearly 2 percent percent at $34.93.

The Scan

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.

US Survey Data Suggests Ancestry Testing Leads Way in Awareness, Use of Genetic Testing Awareness

Although roughly three-quarters of surveyed individuals in a Genetics in Medicine study reported awareness of genetic testing, use of such tests was lower and varied with income, ancestry, and disease history.

Coral Genome Leads to Alternative Amino Acid Pathway Found in Other Non-Model Animals

An alternative cysteine biosynthesis pathway unearthed in the Acropora loripes genome subsequently turned up in sequences from non-mammalian, -nematode, or -arthropod animals, researchers report in Science Advances.

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.